Lly, ABBV, LVS Rebound Selection of shares for the next quarter News ad

The earnings season is when investors receive a report on the progress of companies in their portfolio or in their observation list. The income report, as a rule, is a lagging indicator. This is because headlines tells you about the past performance of the company.

Despite the fact that past results are not an accurate indicator of future performance, many investors still sell the company’s shares when its income falls below analysts.

But over time, your decision on the purchase or sale of shares of the company should be based on what, in your opinion, will happen in the future. That is why one of the closest elements of the company’s income report is the leadership that it gives to the next quarter or year.

We are still in the middle of this season of income, but dozens of companies have already reported income with lower than expected. Nevertheless, many analysts go beyond the headlines and decide that these shares can still be good investments. Here are three shares from companies that have missed profit, but have strong support from analysts.

Demand for GLP-1 drugs remains a perennial catalyst for Lly Stock

Eli Lilly & Co. NYSE: Lly The delivered profit per share in the amount of $ 5.32 on February 6, 2025. Although this number was more than twice as much as in the US dollars in the same quarter in the previous year, it missed the expectations of analysts for 13 cents per share. The company also brought an income of $ 13.53 billion, which was higher than expected at $ 13.43 billion. USA Analysts.

Investors sent shares by about 3% from the moment the report was issued. The fall of earnings is associated with lower prices for the medicine GLP-1, Mounjaro. Nevertheless, Mounjaro sales increased by 60% to $ 3.53 billion. The United States in the quarter, which has more than filled lower prices. Similar revenue growth was registered for Zepbound, his candidate GLP-1 for obesity and TNT, another drug for diabetes of the blockbuster.

Demand for GLP-1 drugs will probably remain strong in 2025, and Lilly also demonstrates a deep pipeline of drugs at all stages of clinical tests. The analyst Eli Lilly predicts to Marketbeat, which has a consensus target price of $ 997.50 for Lly shares, which will be 5.6%. And this goes well with the dividend, which have increased by about 103% over the past five years.

ABBVIE continues to tell a strong story outside Khumir

A similar story was played with Abbvie Inc. NYSE: ABBVThe field of the pharmaceutical giant published an income of 15.10 billion dollars. The United States, which is conveniently exceeded for $ 14.83 billion. But the profit per share is $ 2.16, missed at 82 cents, and 30% lower than the annual similar period (per year). And, as for Eli Lilly, investors bought news, leading ABBV shares by 8% immediately after the announcement.

The ABBVIE installation is mainly concentrated around its blockbuster, Humira, which is currently faced with bi -like competition in Europe and the United States. But with each passage of the quarter, the company shows that other medicines in its arsenal, such as Skyrizi and Rinvoq, help to get a decrease in Humira sales.

And since ABBVIE announced the income on January 31, he announced the approval of FDA on Emblaveo, intravenous treatment with antibiotics, which it was developed with Pfizer Inc. NYSE: PFEThe company will not begin to receive income to the 3rd quarter, but this is another reason to believe that in this quarter the income will not be repeated.

Analysts become a bet that more numbers will be more than gambling

These were rude 12 months for Consumer discretion sharesThe field and this continues to be true for Las Vegas Sands Inc. NYSE: LVSThe field company, which owns a network of hotels and a casino, was lit by four cents to earn money. The number was three cents below on an annual basis. And income of 2.9 billion dollars. The United States is estimated for $ 2.85 billion, but in fact it was flat compared to the previous year.

Nevertheless, analysts remain optimistic on Las -Vegas Sands, expecting an increase in income from the casino, since they expand the potential of the hotel in Macau and the Marina Bay Sands project in Singapore. The Macau, which greatly depends on China, was slowly rising back. However, in the last quarter, a general visit to Macau, by the same, reached the level of 2019.

LVS shares continue to face some risks, especially due to the fact that visiting the provinces with lower GDP in China per capita remains lower than the levels of 2019. Nevertheless, analysts have a targeted price for a bull consensus in the amount of $ 59.58, which is 38.5% more than the shares of shares on February 7, 2025.